Browse the corpus

Alfentanil is a synthetic, short-acting opioid analgesic classified as a small-molecule derivative of fentanyl. This medication is widely used as an analgesic supplement during various surgical procedures or as a primary anesthetic agent in high doses during cardiac surgery in hospital settings. In comparison to analogous anesthetics such as fentanyl and sufentanil, alfentanil exhibits the least potency, has the fastest onset of action, and features the shortest duration of action. Due to its brief duration of action, alfentanil is generally favored for shorter procedures or situations requiring swift alterations in the level of consciousness. The drug has received approval from the U.S. Food and Drug Administration (FDA) as an anesthetic for adults and children undergoing general anesthesia and monitored anesthesia care, highlighting its clinical significance. This activity thoroughly covers crucial aspects of alfentanil usage, including its indications, ideal patient profiles, administration protocols, adverse effects, mechanism of action, and vigilant monitoring strategies. This activity also fosters an interprofessional approach to pain management, elucidating the role of alfentanil within this multidisciplinary framework. Furthermore, the activity highlights the importance of meticulous monitoring practices by healthcare professionals during alfentanil usage, thereby promoting informed decision-making and a coordinated interprofessional approach to efficient and safe pain management across diverse clinical scenarios. Objectives: Identify the appropriate indications for alfentanil usage, distinguishing scenarios where its unique pharmacological properties align with patient needs. Screen patients for contraindications and risk factors associated with alfentanil use, ensuring safe and tailored administration. Assess patients for potential interactions, especially with benzodiazepines or central nervous system depressants, and adjust dosages accordingly to prevent complications. Collaborate with other healthcare professionals to coordinate seamless perioperative care, particularly in scenarios involving alfentanil usage. Access free multiple choice questions on this topic.

Symptoms of alfentanil toxicity are similar to those of other opioid-class medications and include skeletal muscle rigidity, cardiac depression, respiratory depression, and constriction of the pupils. If signs of toxicity develop, healthcare providers should initiate supportive measures, including re-establishing a patent airway (with ventilation if necessary) and providing oxygen or vasopressors in circulatory shock or pulmonary edema cases. The typical choice for reversing alfentanil toxicity is naloxone—an opioid receptor antagonist. Another antidote commonly used for opioid toxicity reversal is nalmefene.[22]

Alfentanil is classified as a Schedule II controlled substance due to its high potential for misuse, with the potential for psychosocial and/or physical dependence. Given the ongoing opioid abuse issue, it is crucial to adopt harm-reducing strategies and technologies in the healthcare field. Interprofessional collaboration involving all members of the healthcare team, including physicians, advanced practice practitioners, nurses, and pharmacists, and the use of prescription drug monitoring programs, is the most effective approach for monitoring and identifying potential abuse of opioid drugs.[23][24][25]